Canada markets open in 2 hours 30 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6910+0.0061 (+0.89%)
At close: 04:00PM EDT
0.6910 0.00 (0.00%)
Pre-Market: 05:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6849
Open0.6993
Bid0.0000 x 3000
Ask0.0000 x 1300
Day's Range0.6636 - 0.7000
52 Week Range0.5000 - 1.3600
Volume288,319
Avg. Volume475,761
Market Cap87.497M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings DateMay 08, 2023 - May 12, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • GlobeNewswire

    Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

    SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments. Key developments from Q4 2022 and year to date include: Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELI

  • GlobeNewswire

    Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

    SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 TRIAL evaluates neoadjuvant trea

  • GlobeNewswire

    Atossa to Present at the Sidoti Small-Cap Virtual Conference

    SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced that the Company will present at the Sidoti Small-Cap Virtual Conference being held March 22-23, 2023. The presentation by Dr. Steven Quay, President and Chief Executive Officer and Kyle Guse, General Counsel and Chief Financial Officer, will take place on Thursday